Your browser doesn't support javascript.
Intraocular injection of KH902 alleviates retinal hypoxia in a mouse model of oxygen-induced retinopathy
Archives of Biological Sciences ; 73(4):447-455, 2021.
Article in English | Web of Science | ID: covidwho-1613485
ABSTRACT
Inhibition of vascular endothelial growth factor (VEGF) has been widely applied in anti-neovascularization therapies. As a novel anti-VEGF agent, KH902 (conbercept) is designed to restrain pathological angiogenesis. However, the effects of KH902 on retinal hypoxia have not been well studied. In a mouse model of oxygen-induced retinopathy (OIR), we assessed retinal hypoxia at postnatal days 14 (P14) and P17, as well as retinal neovascularization (RNV) at P17. In addition, we evaluated the protein level of VEGF and galectin-1 (Gal-1). Changes of the neuroretinal structure were also examined. Our results indicated that KH902 could remit retinal hypoxia in OIR at P14 and P17, which was an exciting novel finding for KH902 function. Additionally, we confirmed that KH902 markedly reduces RNV. Our results indicated that administration of KH902 downregulated VEGF expression, as well as Gal-1. Damage of neuroretinal structure after KH902 injection was not observed, which was also an encouraging result. Our study suggests that KH902 plays a role in alleviating retinal hypoxia and that it could be used for the treatment of other ncovascular ocular diseases.
Keywords

Full text: Available Collection: Databases of international organizations Database: Web of Science Language: English Journal: Archives of Biological Sciences Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: Web of Science Language: English Journal: Archives of Biological Sciences Year: 2021 Document Type: Article